Compumedics Somfit® Commercialisation & Sales Activities Update

September 20, 2022

Compumedics Limited (ASX: CMP) (“Compumedics” or “Company”) is pleased to update the market in relation to various commercialisation activities regarding its Somfit® technology platform.


Sales of the Somfit® services and product have commenced in Australia and in Europe, mainly to research institutions, universities, and elite sports related organisations. These initial sales (about $200,000) have allowed Compumedics to start the real-world validation of the technology and allow the Company to generate publications in support of the use of Somfit® services and product in these settings.


  • Somfit® services and product have also been purchased for two large Insomnia studies currently underway in Australia, which will allow Compumedics to gather data to develop a deep learning algorithm for use in a future Insomnia related product.
  • Somfit® services and product have been purchased for evaluation in Occupational Health and Safety (OH&S) management in remote mining sites.
  • Somfit® services and product have been purchased for evaluation in pre-screening cardiac surgery patients.
  • Somfit® services and product have been purchased for evaluation as a patient monitor in the ICU (intensive care unit) setting.


The go-to market strategy for point of care testing has been developed around an initial focus in Australia and east coast of the USA and is currently being executed, targeting three main areas:


  • The existing Obstructive Sleep Apnea (OSA) Home Sleep Testing (HST) market
  • The primary care market for sleep screening, OSA diagnosis and supporting the diagnosis of Insomnia and circadian rhythm disorders
  • eHealth backbone (Nexus 360) across east coast of USA (a forerunner to home testing)


In August 2022, a leading provider of HST services in Australia signed a Memorandum of Understanding (MoU) to evaluate the Somfit® services and product technology.  They have signed the MOU to use the Somfit® services and product technology exclusively within their current service operations, with an expectation to move 100% of their home sleep tests to the Somfit® services and product technology over a 24-month period, commencing in January 2023, subject to certain evaluation milestones.


About Compumedics Limited

Compumedics Limited [ASX: CMP] is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe and the Middle East.


Executive Chairman Dr. David Burton founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.


Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian governments.


For further information please contact:

Dr David Burton
Executive Chairman, CEO

Compumedics Limited
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

David Lawson
Director, CFO

Compumedics Limited
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

Rod North,
Managing Director

Bourse Communications Pty Ltd
T: +61 3 9510 8309, M: 0408 670 706


Authorised for lodgement by Compumedics Limited’s Board of Directors